| Zygel (cannabidiol gel) / Paragon Biosci |
ACTRN12621000874819: Clinical study of cannabidiol in children, adolescents and young adults with Fragile X syndrome (RECONNECT) |
|
|
| Recruiting | 3 | 250 | | | Zynerba Pharmaceuticals Pty Ltd, Zynerba Pharmaceuticals Pty Ltd | Fragile X Syndrome | | | | |
2021-002542-33: Effects and Safety of Test drug ZYN002, applied as a gel onto the skin of children, adolescents and young adults with a certain hereditary disease called Fragile X Syndrome |
|
|
| Not yet recruiting | 3 | 204 | Europe | ZYN002, Transdermal gel | Zynerba Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc. | Fragile X syndrome (FXS) is a rare genetic disorder caused by the deficiency or absence of Fragile X Messenger Ribonucleoprotein 1 (FMRP), an RNA-binding protein and the gene product of the FMR1 gene. FXS is most commonly caused by silencing of the FMR1 gene due to a trinucleotide repeat expansion. In FXS patients, the relative absence of functional FMRP is associated with critical impairments in neurodevelopment and learning, as well as disruption to other neuronal and non-neuronal functions., Fragile X syndrome (FXS) is a rare disease caused by lack of Fragile X Messenger Ribonucleoprotein 1 due to a faulty gene. It mainly causes learning difficulties in patients., Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | | | | |
| Recruiting | 3 | 250 | Europe, US, RoW | ZYN002 - transdermal gel, cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery), Placebo, Placebo Comparator, Matching Placebo | Zynerba Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc. | Fragile X Syndrome | 05/25 | 05/25 | | |
ZYN2-CL-017, NCT03802799: Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents with FXS |
|
|
| Enrolling by invitation | 2/3 | 450 | Europe, US, RoW | ZYN002 - Cannabidiol Transdermal Gel, Cannabidiol Transdermal Gel | Zynerba Pharmaceuticals, Inc. | Fragile X Syndrome | 08/27 | 08/27 | | |
ACTRN12618000516280: Clinical study of Cannabidiol in children and adolescents with Developmental and Epileptic Encephalopathy |
|
|
| Recruiting | 2 | 55 | | | Zynerba Pharmaceuticals Pty Ltd, Zynerba Pharmaceuticals Pty Ltd | Epilepsy, Developmental disability | | | | |
ACTRN12618001868279: Clinical study Of caNNabidiol in children and adolesCenTs with Fragile X Open-Label Extension (CONNECT-FX OLE) |
|
|
| Recruiting | 2 | 300 | | | Zynerba Pharmaceuticals Pty. Ltd, Zynerba Pharmaceuticals Pty. Ltd. | Fragile X Syndrome | | | | |
ACTRN12619000673145: Clinical Study of Synthetic Cannabidiol in Children and Adolescents with 22q11.2 Deletion Syndrome |
|
|
| Recruiting | 2 | 20 | | | Zynerba Pharmaceuticals Pty Ltd, Zynerba Pharmaceuticals Pty Ltd | Pediatric 22q11.2 deletion syndrome | | | | |
ACTRN12621001512819p: A Single Centre Observational Study to Assess whether a Topically Applied Cannabidiol Gel can Reduce Symptoms of Painful Osteoarthritis of the Hand
|
|
|
| Not yet recruiting | 1/2 | 20 | | | Avecho Biotechnology, Lambert Initiative for Cannabinoid Therapeutics | Osteoarthritis of the hand | | | | |
ACTRN12621001512819: A Single Centre Observational Study to Assess whether a Topically Applied Cannabidiol Gel can Reduce Symptoms of Painful Osteoarthritis of the Hand
|
|
|
| Completed | 1/2 | 20 | | | Avecho Biotechnology, Lambert Initiative for Cannabinoid Therapeutics | Osteoarthritis of the hand | | | | |
ACTRN12617000150347: A Phase 1/2, Open-Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome |
|
|
| Active, not recruiting | N/A | 16 | | | Zynerba Pharmaceuticals, Zynerba Pharmaceuticals Ltd. | Fragile X Syndrome | | | | |
